Singapore markets close in 12 minutes

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
24.22-0.53 (-2.14%)
At close: 04:00PM EDT
24.22 0.00 (0.00%)
After hours: 04:02PM EDT

Agios Pharmaceuticals, Inc.

88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600

Full-time employees389

Key executives

NameTitlePayExercisedYear born
Mr. Brian M. Goff M.B.A.CEO & Director1.23MN/A1969
Ms. Cecilia JonesChief Financial Officer403.36kN/A1975
Mr. James William BurnsCorp. Sec. & Chief Legal Officer660.33kN/A1978
Dr. Sarah Gheuens M.D., Ph.D.Chief Medical Officer and Head of R&D769.2kN/A1980
Dr. Lewis Clayton Cantley Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1946
Dr. Craig B. Thompson M.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/A1953
Dr. Shin-San Su Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1956
Mr. T. J. Washburn Jr.Principal Accounting OfficerN/AN/A1981
Dr. Clive Patience Ph.D.Chief Technical Operations OfficerN/AN/A1964
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2023 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.